Development of Human Anthrax Immune Globulin

人炭疽免疫球蛋白的研制

• 批准号: 8350692
• 负责人: HOPKINS ROBERT
• 金额: $ 192.88万
• 依托单位: EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-28 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8350692
• 关键词: Anthrax disease; Anthrax immune globulin; Clinical Research; Contracts; Drug Kinetics; Human Development; Intravenous; Phase; Safety; Support Contracts; Therapeutic; drug development

The Development of the Human Anthrax Immune Globulin (AIGIV) contract supports non-clinical studies to assess the efficacy of anthrax immune globulin for intravenous use (AIGIV) as a therapeutic for anthrax disease, as well as a Phase I/II clinical study to evaluate the pharmacokinetics and safety of AIGIV.

人类炭疽免疫球蛋白（AIGIV）合同的开发支持非临床研究，以评估静脉注射用炭疽免疫球蛋白（AIGIV）作为炭疽疾病治疗药物的疗效，以及评估AIGIV药代动力学和安全性的I/II期临床研究。